Skip to content
Triangle logo TriangleGet started
← Study library

NCT02724579 · CITED IN SOURCE DOCUMENTS

Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma

An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.

Phase
PHASE2
Status at capture
ACTIVE NOT RECRUITING
Registry last update
2026-07-16

This phase II trial studies how well reduced doses of radiation therapy to the brain and spine (craniospinal) and chemotherapy work in treating patients with newly diagnosed type of brain tumor called WNT)/Wingless (WNT)-driven medulloblastoma. Recent studies using chemotherapy and radiation therapy have been shown to be effective in treating patients with WNT-driven medulloblastoma. However, there is a concern about the late side effects of treatment, such as learning difficulties, lower amounts of hormones, or other problems in performing daily activities. Radiotherapy uses high-energy radiation from x-rays to kill cancer cells and shrink tumors. Drugs used in chemotherapy, such as cisplatin, vincristine sulfate, cyclophosphamide and lomustine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving reduced craniospinal radiation therapy and chemotherapy may kill tumor cells and may also reduce the late side effects of treatment.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

No posted result sections were captured. Registered plans do not establish that a treatment works.

Who could take part
eligibility Criteria
Inclusion Criteria: * Patients must be greater than or equal to 3 years and less than 22 years of age at the time of enrollment * Patients must be newly diagnosed and have: * Eligibility confirmed by rapid central pathology and molecular screening review on APEC14B1: * Classical histologic type (non LC/A) WNT medulloblastoma * Positive nuclear beta-catenin by immunohistochemistry (IHC) * Positive for CTNNB1 mutation by Sanger sequencing * Negative for MYC and MYCN by fluorescence in situ hybridization (FISH) * Patient must have negative lumbar cerebrospinal fluid (CSF) cytology * Note: CSF cytology for staging should be performed no sooner than 14 days post operatively to avoid false positive CSF; ideally, CSF should be obtained between day 14 and day 21 to allow for final staging status before enrollment onto the study; patients with positive CSF cytology obtained 0 to 14 days after surgery should have cytology repeated to determine eligibility and final CSF status; patients with negative CSF cytology from lumbar puncture obtained 0 to 14 days after surgery do not need cytology repeated; patients with negative CSF cytology from lumbar puncture obtained prior to surgery do not need cytology repeated post-operatively * Patients must have eligibility confirmed by Rapid Central Imaging Review on APEC14B1; patients must have =\< 1.5 cm\^2 maximal cross-sectional area of residual tumor; whole brain magnetic resonance imaging (MRI) with and without gadolinium and spine MRI with gadolinium must be performed * Patients must be enrolled, and protocol therapy must be projected to begin, no later than 36 days after definitive diagnostic surgery (day 0) * Peripheral absolute neutrophil count (ANC) \>= 1000/uL * Platelet count \>= 100,000/uL (transfusion independent) * Hemoglobin \>= 8.0 g/dL (may receive red blood cell \[RBC\] transfusions) * Creatinine clearance or radioisotope glomerular filtration rate (GFR) \>= 70 mL/min/1.73 m\^2 or a serum creatinine based on age/gender as follows: * 3 to \< 6 years of age: maximum (max) serum creatinine 0.8 mg/dL (males and females) * 6 to \< 10 years of age: max serum creatinine 1 mg/dL (males and females) * 10 to \< 13 years of age: max serum creatinine 1.2 mg/dL (males and females) * 13 to \< 16 years of age: max serum creatinine 1.5 md/dL (males) and 1.4 md/dL (females) * \>= 16 years of age: max serum creatinine 1.7 mg/dL (males) and 1.4 mg/dL (females) * The threshold creatinine values were derived from the Schwartz formula for estimating GFR utilizing child length and stature data published by the Centers for Disease Control and Prevention (CDC) * Total or direct bilirubin =\< 1.5 x upper limit of normal (ULN) for age, and * Serum glutamate pyruvate (SGPT) (alanine aminotransferase \[ALT\]) =\< 135 U/L (3x ULN); for the purpose of this study, the ULN for SGPT is 45 U/L * Central nervous system function defined as: * Patients with seizure disorder may be enrolled if on anticonvulsants and well controlled * Patients must not be in status epilepticus, a coma or on assisted ventilation at the time of study enrollment * Patients must have receptive and expressive language skills in English, French, or Spanish to complete the QoL and neurocognitive assessments; if a patient meets these criteria but the parent/guardian speaks a language other than English, French, or Spanish, the patient may still be enrolled and tested, and the parent-report measures should be omitted * All patients and/or their parents or legal guardians must sign a written informed consent; assent, when appropriate, will be obtained according to institutional guidelines * All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met Exclusion Criteria: * Patients with metastatic disease by either MRI evaluation (brain and spine) or lumbar CSF cytology are not eligible; patients who are unable to undergo a lumbar puncture for assessment of CSF cytology are ineligible * Patients must not have received any prior radiation therapy or chemotherapy (tumor-directed therapy) other than surgical intervention and/or corticosteroids * Pregnancy and Breast Feeding * Female patients who are pregnant are ineligible due to risks of fetal and teratogenic adverse events as seen in animal/human studies * Lactating females are not eligible unless they have agreed not to breastfeed their infants * Female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained * Sexually active patients of reproductive potential are not eligible unless they have agreed to use an effective contraceptive method for the duration of their study participation * Patients with a history of moderate to profound intellectual disability (i.e., intelligence quotient \[Q)\]=\< 55) are not eligible for enrollment; PLEASE NOTE: Children with a prior history of attention deficit hyperactivity disorder (ADHD) or a specific learning disability (e.g., dyslexia) are eligible for this study. Children with posterior fossa syndrome (also known as cerebellar mutism) are eligible for this study
healthy Volunteers
false
maximum Age
21 Years
minimum Age
3 Years
sex
ALL
std Ages
  1. CHILD
  2. ADULT
Treatment arms and interventions
arm Groups
  1. description
    RADIATION THERAPY: Beginning 4-5 weeks after surgery, patients undergo craniospinal radiation therapy 5 days a week for 6 weeks. MAINTENANCE THERAPY (WEEKS 1, 3, 5, and 7): Beginning 4-6 weeks after completion of radiation therapy patients receive lomustine PO on day 1, vincristine sulfate IV over 1 minute or via minibag on days 1, 8, and 15, and cisplatin IV over 6 hours on day 1. Treatment repeats every 42 days in the absence of disease progression or unacceptable toxicity. MAINTENANCE THERAPY (WEEKS 2, 4, AND 6): Patients receive cyclophosphamide IV over 30-60 minutes on days 1 and 2, mesna IV over 15-30 minutes on days 1 and 2, and vincristine sulfate IV over 1 minute or via minibag on days 1 and 8. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo MRI throughout the trial.
    intervention Names
    1. Drug: Cisplatin
    2. Drug: Cyclophosphamide
    3. Other: Laboratory Biomarker Analysis
    4. Drug: Lomustine
    5. Procedure: Magnetic Resonance Imaging
    6. Radiation: Radiation Therapy
    7. Drug: Vincristine
    8. Drug: Vincristine Sulfate
    label
    Treatment (reduced radiation therapy and chemotherapy)
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. Treatment (reduced radiation therapy and chemotherapy)
    description
    Given IV
    name
    Cisplatin
    other Names
    1. Abiplatin
    2. Blastolem
    3. Briplatin
    4. CDDP
    5. Cis-diammine-dichloroplatinum
    6. Cis-diamminedichloridoplatinum
    7. Cis-diamminedichloro Platinum (II)
    8. Cis-diamminedichloroplatinum
    9. Cis-dichloroammine Platinum (II)
    10. Cis-platinous Diamine Dichloride
    11. Cis-platinum
    12. Cis-platinum II
    type
    DRUG
  2. arm Group Labels
    1. Treatment (reduced radiation therapy and chemotherapy)
    description
    Given IV
    name
    Cyclophosphamide
    other Names
    1. (-)-Cyclophosphamide
    2. 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate
    3. Asta B 518
    4. B 518
    5. B-518
    6. B518
    7. Carloxan
    8. Ciclofosfamida
    9. Ciclofosfamide
    10. Cicloxal
    11. Clafen
    12. Claphene
    type
    DRUG
  3. arm Group Labels
    1. Treatment (reduced radiation therapy and chemotherapy)
    description
    Correlative studies
    name
    Laboratory Biomarker Analysis
    type
    OTHER
  4. arm Group Labels
    1. Treatment (reduced radiation therapy and chemotherapy)
    description
    Given PO
    name
    Lomustine
    other Names
    1. 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea
    2. 1-Nitrosourea, 1-(2-chloroethyl)-3-cyclohexyl-
    3. Belustin
    4. Belustine
    5. CCNU
    6. Cecenu
    7. CeeNU
    8. Chloroethylcyclohexylnitrosourea
    9. Citostal
    10. Gleostine
    11. Lomeblastin
    12. Lomustinum
    type
    DRUG
  5. arm Group Labels
    1. Treatment (reduced radiation therapy and chemotherapy)
    description
    Undergo MRI
    name
    Magnetic Resonance Imaging
    other Names
    1. Magnetic Resonance
    2. Magnetic Resonance Imaging (MRI)
    3. Magnetic resonance imaging (procedure)
    4. Magnetic Resonance Imaging Scan
    5. Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance
    6. MR
    7. MR Imaging
    8. MRI
    9. MRI Scan
    10. MRIs
    11. NMR Imaging
    12. NMRI
    type
    PROCEDURE
  6. arm Group Labels
    1. Treatment (reduced radiation therapy and chemotherapy)
    description
    Undergo craniospinal radiation therapy
    name
    Radiation Therapy
    other Names
    1. Cancer Radiotherapy
    2. Energy Type
    3. ENERGY_TYPE
    4. Irradiate
    5. Irradiated
    6. Irradiation
    7. Radiation
    8. Radiation Therapy, NOS
    9. Radiotherapeutics
    10. Radiotherapy
    11. RT
    12. Therapy, Radiation
    type
    RADIATION
  7. arm Group Labels
    1. Treatment (reduced radiation therapy and chemotherapy)
    description
    Given IV or via minibag
    name
    Vincristine
    other Names
    1. LCR
    2. Leurocristine
    3. VCR
    4. Vincrystine
    type
    DRUG
  8. arm Group Labels
    1. Treatment (reduced radiation therapy and chemotherapy)
    description
    Given IV or via minibag
    name
    Vincristine Sulfate
    other Names
    1. Kyocristine
    2. Leurocristine Sulfate
    3. Leurocristine, sulfate
    4. Oncovin
    5. Vincasar
    6. Vincosid
    7. Vincrex
    8. Vincristine, sulfate
    type
    DRUG
Study design
allocation
NA
intervention Model
SINGLE_GROUP
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
45
type
ESTIMATED
Registered outcome plans (not posted results)
other Outcomes
  1. description
    The proportion of patients classified into each medulloblastoma subgroup will be reported.
    measure
    DNA methylation profiling of medulloblastoma real-time" predictive classification scheme for the SHH, group 3 and group 4 medulloblastoma subgroups according to the Heidelberg classifier
    time Frame
    Within 32 days of definitive surgery
  2. description
    The proportions of children who experienced audiologic, endocrinologic, and peripheral neuropathy toxicities per grade will be estimated along with 95% confidence interval based on an exact binomial distribution.
    measure
    Audiologic and endocrinologic toxicities
    time Frame
    Up to 10 years
primary Outcomes
  1. description
    PFS along with the confidence intervals will be estimated using the Kaplan-Meier method. PFS will also be reported based on central radiology review.
    measure
    Progression-free survival (PFS)
    time Frame
    From the initiation of protocol treatment to the occurrence of any of the following events: disease progression or disease recurrence or death from any cause, assessed up to 10 years
secondary Outcomes
  1. description
    Results will be compared to the results of the molecular screening tests. The sensitivity and specificity comparison between DNA methylation arrays and the standard methods (molecular screening tests for WNT using immunohistochemistry \[IHC\] and CTNNB1 sequencing) will be performed using McNemar's test.
    measure
    Deoxyribonucleic acid (DNA) methylation profiling as real-time classification of WNT-driven medulloblastoma
    time Frame
    Within 32 days of definitive surgery
  2. description
    Neurocognitive function will be measured at 9, 30 and 60 months post diagnosis and will be compared with the neurocognitive outcomes from an age and gender matched ACNS0331 cohort to the WNT patients treated on ACNS1422. Data for all assessments will be available as standardized t-scores. The change over time for each component of the neuropsychological testing will be estimated using the Generalized Estimating Equation (GEE) approach, with the standardized t-scores as the dependent variable and the assessment times as a covariate. Within the ACNS1422 cohort GEE models will also be used to explore associations of changes over time with factors such as gender, age at initiation of radiation therapy, tumor location, number of surgical interventions, etc.
    measure
    Change in neurocognitive function (cognitive, social, emotional and behavioral) according to Children Oncology Group Standard Neuropsychological Battery
    time Frame
    Baseline to up to 60 months post-diagnosis
Full study description
brief Summary
This phase II trial studies how well reduced doses of radiation therapy to the brain and spine (craniospinal) and chemotherapy work in treating patients with newly diagnosed type of brain tumor called WNT)/Wingless (WNT)-driven medulloblastoma. Recent studies using chemotherapy and radiation therapy have been shown to be effective in treating patients with WNT-driven medulloblastoma. However, there is a concern about the late side effects of treatment, such as learning difficulties, lower amounts of hormones, or other problems in performing daily activities. Radiotherapy uses high-energy radiation from x-rays to kill cancer cells and shrink tumors. Drugs used in chemotherapy, such as cisplatin, vincristine sulfate, cyclophosphamide and lomustine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving reduced craniospinal radiation therapy and chemotherapy may kill tumor cells and may also reduce the late side effects of treatment.
detailed Description
PRIMARY OBJECTIVE: I. To estimate the progression-free survival (PFS) of children \>= 3 years of age with wingless-type MMTV integration site family (WNT)-driven average-risk medulloblastoma using reduced craniospinal radiotherapy (CSI) (18 Gray \[Gy\]) with a limited target volume boost to the tumor bed of 36 Gy for a total of 54 Gy and reduced chemotherapy approach (no vincristine \[vincristine sulfate\] during radiotherapy and reduced-dose maintenance chemotherapy) and to monitor the PFS for early evidence that the outcome is unacceptable. SECONDARY OBJECTIVES: I. To prospectively test the hypothesis that deoxyribonucleic acid (DNA) methylation profiling will accurately classify WNT-driven medulloblastoma. II. To prospectively evaluate and longitudinally model the cognitive, social, emotional, behavioral, and quality of life (QoL) functioning of children who are treated with reduced CSI (18 Gy) with a limited target volume boost to the tumor bed (to a total of 54 Gy) and reduced chemotherapy (reduced cisplatin, vincristine, and lomustine \[CCNU\]). EXPLORATORY OBJECTIVES: I. To explore whether DNA methylation profiling of medulloblastoma samples will result in a predictive classification scheme for the Sonic Hedgehog (SHH), Group 3, and Group 4 medulloblastoma subgroups according to the Heidelberg classifier. This will be addressed in a separate biology protocol. II. To describe the audiologic and endocrinologic toxicities, as well as peripheral neuropathy, in children treated with reduced CSI (18 Gy) with a limited target volume boost to the tumor bed (to a total of 54 Gy) and reduced cisplatin and vincristine chemotherapy. OUTLINE: RADIATION THERAPY: Beginning 4-5 weeks after surgery, patients undergo craniospinal radiation therapy 5 days a week for 6 weeks. MAINTENANCE THERAPY (WEEKS 1, 3, 5, and 7): Beginning 4-6 weeks after completion of radiation therapy patients receive lomustine orally (PO) on day 1, vincristine sulfate intravenously (IV) via minibag on days 1, 8, and 15, and cisplatin IV over 6 hours on day 1. Treatment repeats every 42 days in the absence of disease progression or unacceptable toxicity. MAINTENANCE THERAPY (WEEKS 2, 4, AND 6): Patients receive cyclophosphamide IV over 30-60 minutes on days 1 and 2, mesna IV over 15-30 minutes on days 1 and 2, and vincristine sulfate IV via minibag on days 1 and 8. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo magnetic resonance imaging (MRI) throughout the trial. After completion of study treatment, patients are followed up every 3 months for 2 years, every 6 months for 2 years, and then annually for 6 years.
Source references
references
  1. citation
    Mikkelsen MK, Pinto SN, Chiang J, Shimony N, Gajjar A. Evolving Biology and Therapy of WNT-Activated Medulloblastoma. J Natl Compr Canc Netw. 2025 Sep 18;23(10):e257061. doi: 10.6004/jnccn.2025.7061.
    pmid
    40967259
    type
    DERIVED
  2. citation
    Gajjar A, Mahajan A, Bale T, Bowers DC, Canan L, Chi S, Cluster A, Cohen K, Cole B, Coven S, Darlington W, Dorris K, Elster J, Ermoian R, Franson A, George E, Helgager J, Landi D, Lin C, Metrock L, Nanda R, Palmer J, Partap S, Plant A, Pruthi S, Reynolds R, Stearns D, Storm P, Wang A, Wang LD, Whipple N, Zaky W, McMillian N, Ramakrishnan S. Pediatric Central Nervous System Cancers, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology. J Natl Compr Canc Netw. 2025 Mar;23(3):113-130. doi: 10.6004/jnccn.2025.0012.
    pmid
    40073837
    type
    DERIVED
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-7ad944f6deaf1f5cd6122126
      edge id
      nct-edge-1bbdda50164fe85f4990
      requested nct id
      NCT02724579
      primary nct id
      NCT02724579
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source file sha256
      de913ab66946021d86e1a340fa661ff24113f3971f951da28d63bf80bb39bcab
      payload sha256
      a63587c30e6611673e68852198789dec5a0ba9b11d42b34ffbcc499affdd4cf5
      payload
      clinical indication matching status
      not_inferred
      end exclusive
      true
      id
      nct-edge-1bbdda50164fe85f4990
      link basis
      explicit_NCT_identifier_in_acquired_source
      nct id
      NCT02724579
      occurrences
      1. context exact
        tion schema to assign treatment in North American prospective studies (e.g., <a href="/clinicaltrials/NCT01878617">NCT01878617</a> and <a href="/clinicaltrials/NCT02724579">NCT02724579</a>).[<a href="#cit/section_2.74">74</a>]</p> </section><section id="_1902"> <h3 id="_1902_toc">Treatment Option Overview for Childhood
        end
        127217
        exact text
        NCT02724579
        start
        127206
      2. context exact
        o assign treatment in North American prospective studies (e.g., <a href="/clinicaltrials/NCT01878617">NCT01878617</a> and <a href="/clinicaltrials/NCT02724579">NCT02724579</a>).[<a href="#cit/section_2.74">74</a>]</p> </section><section id="_1902"> <h3 id="_1902_toc">Treatment Option Overview for Childhood Medulloblasto
        end
        127230
        exact text
        NCT02724579
        start
        127219
      3. context exact
        /section_2.59">59</a>] Craniospinal radiation dose reduction to 18 Gy is currently being investigated in WNT medulloblastoma patients (<a href="/clinicaltrials/NCT02724579">NCT02724579</a>), the molecular subgroup with the best prognosis.</p></li><li>The <a href="/clinicaltrials/NCT01351870">SIOP-PNET-4 (NCT01351870)</a> study co
        end
        156198
        exact text
        NCT02724579
        start
        156187
      4. context exact
        ">59</a>] Craniospinal radiation dose reduction to 18 Gy is currently being investigated in WNT medulloblastoma patients (<a href="/clinicaltrials/NCT02724579">NCT02724579</a>), the molecular subgroup with the best prognosis.</p></li><li>The <a href="/clinicaltrials/NCT01351870">SIOP-PNET-4 (NCT01351870)</a> study compared daily
        end
        156211
        exact text
        NCT02724579
        start
        156200
      offset unit
      unicode_code_points
      source file
      /tmp/cancer-full-research/nci/raw/c624023f106fb92848.html
      source file sha256
      de913ab66946021d86e1a340fa661ff24113f3971f951da28d63bf80bb39bcab
      source json pointer
      Source null
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source retrieved at
      2026-09-09T23:21:32.468847+00:00
      source string basis
      UTF-8_text_with_universal_newline_translation
      source string sha256
      a109f304435fe602fcc473ec0677179aced88fa575703245f69cd5d95cdd1ea1
      source title
      Childhood Medulloblastoma and Other Central Nervous System Embryonal Tumors Treatment (PDQ®)–Health Professional Version
      source update dates
      1. context
        Updated: April 11, 2025
        datetime
        2025-04-11T12:00:00Z
        display
        April 11, 2025

    Preserved source evidence · Not medical advice